# US 2014/0194598 A1 · B7-related nucleic acids and polypeptides useful for immunomodulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0194598 A1
- Document ID: US20140194598A1
- Status: Published application
- Kind: A1
- Application number: 14/178,360
- Filed: 2014-02-12
- Published: 2014-07-10
- Earliest claimed: 2004-11-22
- Assignees: Bristol-Myers Squibb Company
- Inventors: Glen Eugene Mikesell; Han Chang; Joshua N. Finger; Guchen Yang; Robert James Peach; Henry Shen
- Web page: https://patentgrep.com/patent/US20140194598A1

## CPC

- C07K 14/70532: {B7 molecules, e.g. CD80, CD86}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 7/06: Antianaemics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/18: for HIV
- A61P 31/20: for DNA viruses
- A61P 31/22: for herpes viruses
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2319/00: Fusion polypeptide
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- Y10S 435/81: Packaged device or kit
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.

## Claims

### Claim 1

An isolated nucleic acid molecule encoding a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, 7, 11, 13, and 15.

### Claim 2

An isolated nucleic acid molecule encoding a polypeptide selected from the group consisting of:
a) a polypeptide comprising at least 20 contiguous amino acids of SEQ ID NO:2;
b) a polypeptide comprising at least 210 contiguous amino acids of SEQ ID NO:7;
c) a polypeptide comprising at least 90 contiguous amino acids of SEQ ID NO:11;
d) a polypeptide comprising at least 170 contiguous amino acids of SEQ ID NO:13; and
e) a polypeptide comprising at least 100 contiguous amino acids of SEQ ID NO:15;

### Claim 3

An isolated nucleic acid molecule that encodes a polypeptide comprising an amino acid sequence selected from the group consisting of:
a) an amino acid sequence that is at least 90% identical to SEQ ID NO:2;
b) an amino acid sequence that is at least 90% identical to SEQ ID NO:7;
c) an amino acid sequence that is at least 99% identical to SEQ ID NO:11;
d) an amino acid sequence that is at least 99.5% identical to SEQ ID NO:13;
e) an amino acid sequence that is at least 98% identical to SEQ ID NO:15;

### Claim 4

An isolated nucleic acid molecule comprising nucleotide sequence selected from the group consisting of SEQ ID NO:1, 3, 6, 10, 12, and 14.

### Claim 5

An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:
a) a nucleotide sequence comprising at least 60 contiguous nucleotides of SEQ ID NO:1 or SEQ ID NO:3;
b) a nucleotide sequence comprising at least 630 contiguous nucleotides of SEQ ID NO:6;
c) a nucleotide sequence comprising at least 270 contiguous nucleotides of SEQ ID NO:10;
d) a nucleotide sequence comprising at least 410 contiguous nucleotides of SEQ ID NO:12; and
e) a nucleotide sequence comprising at least 300 contiguous nucleotides of SEQ ID NO:14;

### Claim 6

An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:
a) a nucleotide sequence comprising at least 25 contiguous nucleotides of SEQ ID NO:1 or SEQ ID NO:3;
b) a nucleotide sequence comprising at least 305 contiguous nucleotides of SEQ ID NO:6;
c) a nucleotide sequence comprising at least 255 contiguous nucleotides of SEQ ID NO:10;
d) a nucleotide sequence comprising at least 310 contiguous nucleotides of SEQ ID NO:12; and
e) a nucleotide sequence comprising at least 240 contiguous nucleotides of SEQ ID NO:14;

### Claim 7 (depends on 1, 2, 3, 4, 5)

An isolated nucleic acid molecule comprising a sequence which is complementary to the sequence of the nucleic acid molecule according to any one of claims 1-5.

### Claim 8 (depends on 6)

An isolated nucleic acid molecule comprising a sequence which is complementary to the sequence of the nucleic acid molecule according to claim 6.

### Claim 9

An isolated nucleic acid molecule comprising:
a) a nucleotide sequence encoding an extracellular domain of an amino acid sequence selected from the group consisting of SEQ ID NO:2, 7, 11, 13, and 15; and
b) a nucleotide sequence encoding an Fc domain of immunoglobulin G.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6)

A vector comprising the nucleic acid molecule according to any one of claims 1-6.

### Claim 11 (depends on 7, 8)

A vector comprising the nucleic acid molecule according to any one of claims 7-8.

### Claim 12 (depends on 9)

A vector comprising the nucleic acid molecule according to claim 9.

### Claim 13 (depends on 10)

A host cell comprising the vector according to claim 10, wherein the host cell is selected from the group consisting of bacterial, yeast, insect, mammalian, and plant cells.

### Claim 14 (depends on 11)

A host cell comprising the vector according to claim 11, wherein the host cell is selected from the group consisting of bacterial, yeast, insect, mammalian, and plant cells.

### Claim 15 (depends on 12)

A host cell comprising the vector according to claim 12, wherein the host cell is selected from the group consisting of bacterial, yeast, insect, mammalian, and plant cells.

### Claim 16 (depends on 1, 2, 3, 4, 5)

An isolated polypeptide encoded by the nucleic acid molecule according to any one of claims 1-5.

### Claim 17 (depends on 9)

An isolated polypeptide encoded by the nucleic acid molecule according to claim 9.

### Claim 18 (depends on 16)

An isolated antibody that binds to the polypeptide according to claim 16.

### Claim 19 (depends on 18)

The antibody according to claim 18 which is monoclonal.

### Claim 20 (depends on 19)

A hybridoma cell which produces the antibody according to claim 19.

### Claim at position 21

21-52. (canceled)